Search Results

Marengo Therapeutics, Inc. today announced that its lead program, STAR0602, is the subject of an article published in the latest edition of Science Translational Medicine.

Marengo Therapeutics, Inc. today announced a publication in Science Advances describing the novel immunological effects of its foundational anti-Vβ chain TCR targeting antibodies on human T cells.

This clinical candidate reflects a productive collaboration since the strategic partnership was signed in August 2022.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Ipsen and Marengo Therapeutics, Inc. announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the clinic.

Marengo Therapeutics, Inc., a company pioneering novel immuno-therapeutics targeting the T cell receptor (TCR) Vβ to selectively activate the right T cell subsets to fight cancer, today announced the appointment of Kevin Chin, M.D., M.S., as Chief Medical Officer.

Marengo Therapeutics, Inc., a company pioneering novel immuno-therapeutics targeting the T cell receptor (TCR) Vβ repertoire to fight cancer and other diseases, today announced that the company will present a late-breaking abstract at the upcoming American Association for Cancer Research (AACR) Annual Meeting, held April 14-19 in Orlando, Florida.

Marengo Therapeutics, Inc today announced the formation of its Scientific Advisory Board (SAB).

Marengo Therapeutics, Inc., a company pioneering novel therapeutics that directly target the Vβ chain of the T cell receptor (TCR) to activate the right T cell subsets to fight cancer, today announced the appointment of Svetlana Makhni as Chief Financial Officer, further bolstering Marengo’s C-suite leadership credentials.

Marengo Therapeutics, Inc., a company pioneering novel therapeutics targeting the T cell receptor (TCR) Vβ to selectively activate the right T cell subsets to fight cancer, today announced that the first patient has been dosed in its ongoing clinical trial of STAR0602 (START-001).